13G INITIAL MONTHLY FILING (AGLE)

Company

Spyre Therapeutics, Inc.

Filed

May 9, 2016

Accession Number

0000053417-16-000378

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →